ROVI signs a contract with Farmalíder for the manufacturing of oral forms


No votes yet
 
Related
​Operating revenue in the first half of 2025 was 314.6 million euros, a 4% decrease on the first half of 2024, mainly due to the...
3 min
24/07/2025
  Madrid, 10 July 2025. Laboratorios Farmacéuticos ROVI, S.A. (“ROVI”) announces that, on 9 July 2025, the Technological...
4 min
10/07/2025
ROVI continues with its shareholder remuneration policy after completing the third consecutive share buyback programme last year and...
5 min
18/06/2025